University of Pennsylvania

Inovio Pharmaceuticals, Inc.

The Wistar Institute

Other

Apollon, Inc.

Drexel University

Bp Corporation North America Inc.

Colorado State University Research Foundation

Vgx Pharmaceuticals, Inc.

Institut De Recherches Cliniques De Montreal

Dsm IP Assets B.v.

Cargill Inc.

Universitéde Montreal

Verenium Corporation

Basf Enzymes LLC

David B Weiner

Bin Wang

Mark Joseph Burk

Jian Yan

Karuppiah Muthumani

Niranjan Y Sardesai

Matthew P Morrow

William Valentine Williams

Mathura P Ramanathan

Bernadette Ferraro

Kar Muthumani

Velpandi Ayyavoo

Michele Kutzler

Ruxandra Draghia-Akli

Ami Patel

David Nathan Levy

Devon Shedlock

Patricia A Brown

Amir S Khan

Dominick J Laddy

Douglas R Kern

Kenneth E Ugen

Joo-Sung Yang

Mark I Greene

Michael Agadjanyan

Toby Howard Richardson

Robert M Williams

Paula M Hicks

Peter Luginbuhl

Lishan Zhao

Ellen Burke

Hwai Wen Chang

Nelson Robert Barton

Steven John Gort

Grace DeSantis

David E Lam

Connie Jo Hansen

Kate Broderick

Sara C McFarlan

Christopher Solheid

Fernando A Sanchez-Riera

Geoff Hazlewood

Shaun Healey

Anna Slager

Neil Cooch

David Blum

Erin Kathleen Marasco

Analia Bueno

Nyamekye Obeng-Adjei

Daniel Villarreal

Yosef Refaeli

Sundarasamy Mahalingam

Mamata Patel

Donghui Zhang

Thomas Kieber-Emmons

Megan Wise

Jewell Walters

Elizabeth Duperret

Sarah Elliott

Veronica Scott

Mark J Holterman

Thanadavarayan Nagashunmugam

Jong J Kim

Jean D Boyer

Michael Madaio

Trevor R F Smith

Alfredo Perales Puchalt

Krystle A Lang

Mervyn L De Souza

Joslin M Cuenca

Rodney A Bowling

Seleeke Flingai

Jeong-Im Sin

Jeffrey A Cohen

Rafick P Sekaly

Thomas Todaro

Timothy Hitchman

Richard A Carrano

Andrew Y Choo

Kristine Chang

Mircea Podar

Emma L Reuschel

Daniel Choo

Kimberly A Kraynyak

Alexander Varvak

Brian J Brazeau

Thomas Woodward

Charles Hancock

Charles Reed

Sherry Kollmann

Krystle A Lang Kuhs

Jon Prigge

Lauren A Hirao

Emile Mohler

Geoffrey Ouma

Mathew P Morrow

Natalie Hutnick

Michael A Chattergoon

An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.

Vaccines against Zika virus

The present invention relates to compositions and methods for treating and/or preventing Canine Distemper Virus (CDV) in mammals susceptible to CDV.

Canine distemper vaccines and methods of treatment using the same

An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one Nipah virus (NiV) antigen that elicits an immune response in a mammal against NiV virus, and methods of use thereof.

Vaccines against Nipah virus, and methods of using same

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.

DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)

The invention includes a vaccine comprising an antigen and IL-21. The invention also includes methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

Vaccines having an antigen and interleukin-21 as an adjuvant

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensusglycoproteinimmunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response againstare disclosed. Method of preventingand methods of treating individuals infected withare disclosed. Consensusproteins are disclosed.

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets CTLA-4. The disclosure also provides a method of preventing and/or treating disease, such as cancer, in a subject using the composition of the invention.

DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer

Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.

Mayaro virus consensus antigens, DNA antibody constructs for use against Mayaro virus, and combinations thereof

Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.

Optimized synthetic consensus immunogenic compositions targeting chondroitin sulfate proteoglycan 4 (CSPG4)

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Ebola virus infection in a subject using said composition and method of generation.

DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets PCSK9. The disclosure also provides a method of preventing and/or treating disease, such as cardiovascular disease or hypercholesterolemia, in a subject using the composition of the invention.

Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use

Provided herein are sequences ofspp. liver stage exported proteins as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against malaria using the expression constructs provided herein.

Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

Disclosed herein are compositions comprising structurally modified DNA encoded antibodies (DMAbs), methods of structurally modifying DMAbs, and methods of using structurally modified DMAbs.

Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.

Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom

Growing community of inventors

Merion, PA, United States of America

David B Weiner